Analyst Glen Santangelo of Jefferies maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $23.00.
Glen Santangelo has given his Buy rating due to a combination of factors that suggest a positive outlook for Teva Pharmaceuticals. The company has improved its transparency regarding its FY25 guidance, which has helped set more realistic expectations for the first quarter. This increased clarity is expected to alleviate investor concerns and could act as a catalyst for the stock if there are any positive surprises.
Additionally, management’s confidence in the company’s ability to grow EBITDA in the coming years is supported by several initiatives. These include revenue growth from innovative products, new product launches including biosimilars, and cost-saving programs aimed at improving manufacturing efficiency and organizational effectiveness. Despite anticipated challenges in 2026, such as the gRevlimid headwinds, the potential for biosimilars to offset these challenges is seen as a positive. The current valuation does not fully reflect the growth potential in key areas, suggesting room for further expansion. Therefore, the Buy rating is reiterated with a price target of $23.
Santangelo covers the Healthcare sector, focusing on stocks such as Phreesia, Align Tech, and DENTSPLY SIRONA. According to TipRanks, Santangelo has an average return of 3.7% and a 49.56% success rate on recommended stocks.
In another report released yesterday, Piper Sandler also reiterated a Buy rating on the stock with a $30.00 price target.